The authors discuss the combined use of androgen deprivation therapy and image-guided radiotherapy (IGRT) in aggressive, localized prostate cancer. They also describe how it is imperative to identify the patients who would benefit from this combined-modality therapy relative to the use of IGRT alone and the opportunities for more personalized approaches in treating this disease.
- Jennifer A. Locke
- Alan Dal Pra
- Robert G. Bristow
